Abstract
Background and aims: Recently, it has been reported that rho-kinase that participates in the regulation of vascular tonus, spasm, and remodeling in response to smooth muscle constriction, is involved in the atherosclerosis, inflammation, and hypertention (1). Furthermore, rho-kinase is involved in nitric oxide (NO), free radical, resulting in the neuronal cell death (2). Nevertheless, the mechanism of rho-kinase on the ischemic brain have not been fully understood. The aim of this study is, therefore, to determine whether a newly rho-kinase inhibitor, fasudil, which is a myosin light chain kinase inhibitor and have strong inhibition of rho-kinase, would prevent neuronal cell death following transient focal ischemia in rats compared to a free radical scavenger, edaravone , which is the first clinical neuroprotective agent used in Japan for the treatment of acute stroke patients. Methods: Sprague-Dawley rats were subjected to MCAo using an intraluminal suture technique for 90 minutes (3). The rats were reperfused for 24 hours and decapitated for infarct and edema analysis (4). Animals were randomly divided into the following four groups. (I) vehicle-treated control group (II) low dose of fasudil (3.0 mg/kg)-treated group (III) high dose of fasudil (10.0 mg/kg)-treated group (IV) edaravone-treated group. A rho-kinase inhibitor-treated animals received a continuous injection of fasudil (3.0 or 10.0 mg/kg) intravenously for 60 minutes after the onset of ischemia, while vehicle-treated groups received same dose of vehicle. Edaravone-treated animals received twice injection of edaravone (3.0 mg/kg) intravenously immediately after the reperfusion and 30 minutes after reperfusion. During ischemia, temporal muscle and rectal temperatures were monitored and maintained at 37 degrees in the experimental animals. Neurological symptom evaluations (posture and hemiplegia) were performed immediately before infarct and edema analysis. Furthermore, cortical cerebral blood flow was measured during ischemia and reperfusion. Results: The cortical and striatal infarct volume in the edaravone-treated group was significantly less than those in the vehicle-treated control group I (p
| Original language | English |
|---|---|
| Journal | Journal of Cerebral Blood Flow and Metabolism |
| Volume | 27 |
| Issue number | SUPPL. 1 |
| Publication status | Published - Nov 13 2007 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Neuroscience(all)
- Endocrinology, Diabetes and Metabolism
Cite this
A rho-kinase inhibitor prevents apoptosis-induced neuronal cell death following transient focal ischemia in rats. / Kamiya, Tatsushi; Inaba, Toshiki; Nito, Chikako; Ueda, Masayuki; Kato, Kengo; Suda, Satoshi; Hayashi, Takeshi; Deguchi, Kentaro; Yamashita, Toru; Sehara, Yoshihide; Tsuchiya, Atsushi; Han, Zhe Zhang; Lukic, Violeta; Katayama, Yasuo; Abe, Koji.
In: Journal of Cerebral Blood Flow and Metabolism, Vol. 27, No. SUPPL. 1, 13.11.2007.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A rho-kinase inhibitor prevents apoptosis-induced neuronal cell death following transient focal ischemia in rats
AU - Kamiya, Tatsushi
AU - Inaba, Toshiki
AU - Nito, Chikako
AU - Ueda, Masayuki
AU - Kato, Kengo
AU - Suda, Satoshi
AU - Hayashi, Takeshi
AU - Deguchi, Kentaro
AU - Yamashita, Toru
AU - Sehara, Yoshihide
AU - Tsuchiya, Atsushi
AU - Han, Zhe Zhang
AU - Lukic, Violeta
AU - Katayama, Yasuo
AU - Abe, Koji
PY - 2007/11/13
Y1 - 2007/11/13
N2 - Background and aims: Recently, it has been reported that rho-kinase that participates in the regulation of vascular tonus, spasm, and remodeling in response to smooth muscle constriction, is involved in the atherosclerosis, inflammation, and hypertention (1). Furthermore, rho-kinase is involved in nitric oxide (NO), free radical, resulting in the neuronal cell death (2). Nevertheless, the mechanism of rho-kinase on the ischemic brain have not been fully understood. The aim of this study is, therefore, to determine whether a newly rho-kinase inhibitor, fasudil, which is a myosin light chain kinase inhibitor and have strong inhibition of rho-kinase, would prevent neuronal cell death following transient focal ischemia in rats compared to a free radical scavenger, edaravone , which is the first clinical neuroprotective agent used in Japan for the treatment of acute stroke patients. Methods: Sprague-Dawley rats were subjected to MCAo using an intraluminal suture technique for 90 minutes (3). The rats were reperfused for 24 hours and decapitated for infarct and edema analysis (4). Animals were randomly divided into the following four groups. (I) vehicle-treated control group (II) low dose of fasudil (3.0 mg/kg)-treated group (III) high dose of fasudil (10.0 mg/kg)-treated group (IV) edaravone-treated group. A rho-kinase inhibitor-treated animals received a continuous injection of fasudil (3.0 or 10.0 mg/kg) intravenously for 60 minutes after the onset of ischemia, while vehicle-treated groups received same dose of vehicle. Edaravone-treated animals received twice injection of edaravone (3.0 mg/kg) intravenously immediately after the reperfusion and 30 minutes after reperfusion. During ischemia, temporal muscle and rectal temperatures were monitored and maintained at 37 degrees in the experimental animals. Neurological symptom evaluations (posture and hemiplegia) were performed immediately before infarct and edema analysis. Furthermore, cortical cerebral blood flow was measured during ischemia and reperfusion. Results: The cortical and striatal infarct volume in the edaravone-treated group was significantly less than those in the vehicle-treated control group I (p
AB - Background and aims: Recently, it has been reported that rho-kinase that participates in the regulation of vascular tonus, spasm, and remodeling in response to smooth muscle constriction, is involved in the atherosclerosis, inflammation, and hypertention (1). Furthermore, rho-kinase is involved in nitric oxide (NO), free radical, resulting in the neuronal cell death (2). Nevertheless, the mechanism of rho-kinase on the ischemic brain have not been fully understood. The aim of this study is, therefore, to determine whether a newly rho-kinase inhibitor, fasudil, which is a myosin light chain kinase inhibitor and have strong inhibition of rho-kinase, would prevent neuronal cell death following transient focal ischemia in rats compared to a free radical scavenger, edaravone , which is the first clinical neuroprotective agent used in Japan for the treatment of acute stroke patients. Methods: Sprague-Dawley rats were subjected to MCAo using an intraluminal suture technique for 90 minutes (3). The rats were reperfused for 24 hours and decapitated for infarct and edema analysis (4). Animals were randomly divided into the following four groups. (I) vehicle-treated control group (II) low dose of fasudil (3.0 mg/kg)-treated group (III) high dose of fasudil (10.0 mg/kg)-treated group (IV) edaravone-treated group. A rho-kinase inhibitor-treated animals received a continuous injection of fasudil (3.0 or 10.0 mg/kg) intravenously for 60 minutes after the onset of ischemia, while vehicle-treated groups received same dose of vehicle. Edaravone-treated animals received twice injection of edaravone (3.0 mg/kg) intravenously immediately after the reperfusion and 30 minutes after reperfusion. During ischemia, temporal muscle and rectal temperatures were monitored and maintained at 37 degrees in the experimental animals. Neurological symptom evaluations (posture and hemiplegia) were performed immediately before infarct and edema analysis. Furthermore, cortical cerebral blood flow was measured during ischemia and reperfusion. Results: The cortical and striatal infarct volume in the edaravone-treated group was significantly less than those in the vehicle-treated control group I (p
UR - http://www.scopus.com/inward/record.url?scp=36349030168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36349030168&partnerID=8YFLogxK
M3 - Article
VL - 27
JO - Journal of Cerebral Blood Flow and Metabolism
JF - Journal of Cerebral Blood Flow and Metabolism
SN - 0271-678X
IS - SUPPL. 1
ER -